Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Prostatic Neoplasms 8 Leukemia 8 Burkitt Lymphoma 7 Recurrence 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma 3 Leukemia, Biphenotypic, Acute 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, B-Cell 2 Leukemia, Myeloid, Acute 2 Rhabdoid Tumor 1 Plasmablastic Lymphoma 1 Pituitary Neoplasms 1 Pituitary Diseases 1 Pancreatic Neoplasms 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Neoplasms 1 Leukemia, T-Cell 1 Leukemia, Mast-Cell 1 Leukemia, Lymphoid 1 Hodgkin Disease 1 Hematologic Neoplasms 1

Interventions

benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Panitumumab 1 Minocycline 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Fulvestrant 1 Erlotinib Hydrochloride 1 Dapsone 1 Clindamycin 1 Anti-Bacterial Agents 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Exanthema × Hydrocortisone × Clear all

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡